Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 19, 2024
- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme (GBM) -
Read more at globenewswire.comNASDAQ:DRTSW (5/27/2025, 8:16:35 PM)
0.25
+0 (+0.04%)
NASDAQ:DRTS (5/29/2025, 11:53:32 AM)
3.0468
+0.07 (+2.24%)
Find more stocks in the Stock Screener
